New Millennium Group’s Roivant Sciences ROIV Stock Holding History

New Millennium Group’s Portfolio ROIV Stock Details ROIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-54	Closed	-$639	–	602
2024 Q4	$639	Buy	+54	New	+$638	﹤0.01%	510

Other funds holding ROIV

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

PSC

Patient Square Capital Menlo Park, California $564M AUM 261.3% 1-Year Est. Return

New Millennium Group's ROIV Position: Q1 2025 in Review

New Millennium Group sold out of Roivant Sciences (ROIV) in Q1 2025, closing a stake of 54 shares — an estimated $639 sold.

New Millennium Group first reported a position in ROIV in Q4 2024 and held it in 1 quarter. The position peaked at $639 in Q4 2024. 312 funds tracked by Wall St. Rank hold ROIV as of Q1 2025.

New Millennium Group reported no remaining Roivant Sciences position as of Q1 2025 after selling out during the quarter.
New Millennium Group sold 54 Roivant Sciences shares in Q1 2025, an estimated $639.
New Millennium Group first reported a position in Roivant Sciences in Q4 2024 and held it in 1 quarter.
New Millennium Group's Roivant Sciences position peaked at $639 in Q4 2024.
312 funds tracked by Wall St. Rank held Roivant Sciences as of Q1 2025.

Based on New Millennium Group's 13F filing for Q1 2025, filed 25 Apr 2025.